1,25（OH）_2D_3缺失对膜内和软骨内成骨影响的比较研究

目的：比较1,25（OH）2D3缺失对膜内成骨和软骨内成骨影响的不同。方法：用免疫组织化学染色、HE染色和Western-blot等方法检测6周龄的野生型（wild type,WT）和1琢（OH）ase-/-小鼠的颅骨和股骨干骺端骨组织中I型胶原和甲状旁腺素受体（parathyroid hormone receptor,PTHR）的表达水平。结果：和WT小鼠相比较,1 ase-/-小鼠颅骨的I型胶原阳性面积明显减少,但是干骺端I型胶原阳性面积明显增加,差异有显著性（P〈0.01）;1琢（OH）ase-/-小鼠颅骨成骨细胞计数明显减少,差异存在统计学意义（P〈0.05）;但是干骺端成骨细胞计数明显增加,差异有显著性（P〈0.01）;1琢（OH）ase-/-小鼠颅骨的PHTR表达水平明显减少,但是在干骺端PHTR表达水平明显增加,差异均有显著性（P〈0.01）。结论：1,25（OH）2D3缺乏导致小鼠膜内成骨方式骨形成减少,而软骨内成骨骨形成增加。     

不明原因复发性流产再次妊娠患者血清1,25(OH)2D3、sTim-3与Th17/Treg免疫失衡和妊娠结局的关系

摘要 目的：探讨不明原因复发性流产（URSA）再次妊娠患者血清1,25-二羟维生素D3[1,25（OH)）₂D₃]、可溶性T细胞免疫球蛋白黏蛋白分子3（sTim-3）与辅助性T细胞17（Th17）/调节性T细胞（Treg）免疫失衡和妊娠结局的关系。方法：选择于湖南省妇幼保健院2020年1月~2022年1月就诊的62例URSA再次妊娠患者作为研究组,另选择同期进行孕检的正常早孕妇女30例作为对照组。比较两组孕早期血清1,25(OH) ₂D₃、sTim-3及外周血Th17细胞、Treg细胞水平、Th17/Treg比值。Pearson法分析URSA再次妊娠患者血清1,25(OH) ₂D₃、sTim-3与外周血Th17细胞、Treg细胞水平、Th17/Treg比值平的相关性。根据URSA再次妊娠患者妊娠结局的不同分为妊娠成功分娩组和妊娠再次流产组,比较两组孕早期血清1,25(OH) ₂D₃、sTim-3与外周血Th17细胞、Treg细胞水平、Th17/Treg比值。受试者工作特征（ROC）曲线分析血清1,25(OH) ₂D₃、sTim-3与外周血Th17细胞、Treg细胞水平、Th17/Treg比值对妊娠结局的预测价值。结果：研究组血清sTim-3、外周血Th17细胞水平、Th17/Treg比值高于对照组,血清1,25(OH) ₂D₃、外周血Treg细胞水平低于对照组（P<0.05）。Pearson相关分析显示,URSA再次妊娠患者血清1,25(OH) ₂D₃与血清sTim-3、外周血Th17细胞水平、Th17/Treg比值呈负相关,与Treg细胞水平呈正相关（P<0.05）;血清sTim-3与外周血Treg细胞水平呈负相关,与Th17细胞水平、Th17/Treg比值呈正相关（P<0.05）。妊娠再次流产组血清sTim-3、外周血Th17细胞水平、Th17/Treg比值高于妊娠成功分娩组,血清1,25(OH) ₂D₃、外周血Treg细胞水平低于妊娠成功分娩组（P<0.05）。ROC曲线分析显示,血清1,25(OH) ₂D₃、sTim-3及外周血Th17细胞、Treg细胞水平及Th17/Treg比值均可预测URSA再次妊娠患者妊娠再次流产的发生风险,且上述指标联合检测的预测效能更高。结论：血清1,25(OH) ₂D₃水平异常降低、sTim-3水平异常升高可导致Th17/Treg免疫失衡,导致URSA再次妊娠患者再次发生流产。上述指标联合检测对URSA再次妊娠患者妊娠再次流产的预测效能更高。     

早产儿急性呼吸窘迫综合征血清1,25-(OH)2D3、PGRN、SIRT1、CTRP3水平与炎症反应和预后的关系研究

摘要 目的：探讨不同病情严重程度早产儿急性呼吸窘迫综合征（ARDS）血清1,25-二羟维生素D₃（1,25-(OH) ₂D₃）、颗粒体蛋白前体（PGRN）、沉默信息调节因子2相关酶1（SIRT1）、C1q/肿瘤坏死因子相关蛋白3（CTRP3）的变化，分析其与炎症反应和预后的关系。方法：选择2018年10月至2019年12月安徽省妇幼保健院收治的ARDS早产儿100例作为ARDS组，另选取同期在我院出生的健康新生儿60例作为对照组。根据《"新生儿急性呼吸窘迫综合征"蒙特勒标准（2017年版）》的病情判定标准将ARDS早产儿分为轻度组（n=40）、中度组（n=32）、重度组（n=28），比较不同病情严重程度ARDS早产儿血清1,25-(OH) ₂D₃、PGRN、SIRT1、CTRP3、炎症反应指标肿瘤坏死子因子-α（TNF-α）、白细胞介素-6（IL-6）、白细胞介素-1β（IL-1β）水平变化，采用Pearson法分析ARDS早产儿血清1,25-(OH) ₂D₃、PGRN、SIRT1、CTRP3与炎症反应指标的相关性。另根据ARDS组患儿预后情况分为预后良好组（n=65）和预后不良组（n=35），采用单因素和多因素Logistic回归分析影响ARDS早产儿预后不良的危险因素。结果：ARDS组血清1,25-(OH) ₂D₃、SIRT1、CTRP3、PGRN水平明显低于对照组（P<0.05），ARDS组血清TNF-α、IL-6、IL-1β水平明显高于对照组（P<0.05）。不同病情严重程度ARDS早产儿血清1,25-(OH) ₂D₃、PGRN、SIRT1、CTRP3、炎症反应指标比较差异有统计学意义（P<0.05）。ARDS早产儿血清1,25-(OH) ₂D₃、PGRN、SIRT1、CTRP3水平与TNF-α、IL-6、IL-1β水平呈负相关（P<0.05）。多因素Logistic回归分析结果显示，低出生体重、肺表面活性物质（PS）使用次数≥3次、出现低白蛋白血症是影响ARDS早产儿预后不良的危险因素（P<0.05），血清1,25-(OH)2D3（较高）、PGRN（较高）、SIRT1（较高）、CTRP3（较高）是ARDS早产儿预后不良的保护因素（P<0.05）。结论：血清1,25-(OH) ₂D₃、PGRN、SIRT1、CTRP3可能参与ARDS早产儿的炎症反应过程，与ARDS早产儿的病情进展及预后密切相关，检测血清1,25-(OH) ₂D₃、PGRN、SIRT1、CTRP3有助于评估ARDS早产儿的预后。     

外源H2O2和·OH对大麦幼苗根系线粒体膜脂和流动性的伤害

以大麦(HordeumvulgareL.)为材料,研究了外源H2O2和*OH对大麦根系呼吸速率、线粒体膜流动性和膜脂脂肪酸组成的影响。结果表明,10mmol/LH2O2或·OH处理4d,大麦幼苗根系呼吸速率和线粒体膜脂不饱和脂肪酸含量及脂肪酸不饱和指数下降,线粒体膜脂荧光强度增加,膜流动性下降,且H2O2或·OH处理浓度(在0.1～10mmol/L范围内)越高,膜脂流动性下降越明显。H2O2和·OH处理的同时加入同浓度的抗坏血酸(AsA)和甘露醇,膜流动性明显增强或恢复。     

等渗Ca（NO3）2和NaCl胁迫对黄瓜砧用南瓜幼苗生长和活性氧代谢的影响

以黄瓜砧用黑籽南瓜和白籽南瓜幼苗为材料,通过营养液栽培研究了等渗Ca(NO3)2和NaCl胁迫对南瓜幼苗生长和活性氧代谢的影响。结果表明,不同盐胁迫下两砧木幼苗生长和抗氧化系统活性均受到不同程度抑制;与黑籽南瓜相比,白籽南瓜‘青砧1号’植株的生物量和SOD、POD和CAT活性均较高,而盐害指数、膜相对透性、MDA含量及O2.-产生速率则明显降低。等渗Ca(NO3)2和NaCl对两砧木南瓜幼苗的盐胁迫效应不同,Ca(NO3)2胁迫对砧木生长的抑制作用及盐害指数、膜相对透性、MDA含量、O2.-产生速率均小于等渗的NaCl处理,而其SOD、POD、CAT活性高于NaCl处理。可见,白籽南瓜‘青砧1号’具有较强的生长势和有效清除体内活性氧能力,有效降低膜质过氧化伤害程度,这是其耐盐性高于黑籽南瓜的重要原因;Ca(NO3)2处理使两砧木幼苗细胞受氧化损伤程度较轻,对植株生长的抑制程度明显低于等渗的NaCl。     

不同黄瓜品种幼苗对等渗Mg（NO3）2和NaCl胁迫的生理响应

以3个不同类型的黄瓜品种为试材,采用营养液培养方法,研究等渗Mg(NO3)2和Na Cl胁迫对黄瓜幼苗生长、叶片膜脂过氧化、抗氧化酶活性以及渗透调节物质的影响,采用隶属函数法对其耐盐性进行综合评价.结果表明:与对照相比,60、80 mmol·L-1Mg(NO3)2和等渗90、120 mmol·L-1Na Cl胁迫下,随盐浓度的增加,3种不同生态类型的黄瓜品种幼苗株高、茎粗、叶面积、地上部和地下部干鲜质量及抗氧化酶活性显著降低,盐浓度越高,受抑制程度越高,丙二醛含量显著升高、增幅变大,膜脂过氧化程度加重,其中‘SJ31-1’的生物量及超氧化物歧化酶(SOD)、过氧化物酶(POD)、过氧化氢酶(CAT)活性下降幅度及丙二醛含量上升幅度均小于其他品种.等渗浓度的Mg(NO3)2比Na Cl对黄瓜幼苗的抑制程度大,浓度越大差异越显著.脯氨酸、可溶性蛋白和可溶性糖含量变化存在基因型和盐类型的差异.盐胁迫后,‘SJ31-1’的脯氨酸含量增幅最大,‘鲁白19号’的可溶性糖含量增幅最大,‘新泰密刺’介于两者之间.Na Cl胁迫下,不同黄瓜品种渗透调节物质以可溶性糖和可溶性蛋白为主,而Mg(NO3)2胁迫下以脯氨酸和可溶性蛋白为主.不同黄瓜品种耐盐性的综合评价次序为‘SJ31-1’>‘新泰密刺’>‘鲁白19号’.     

Cu(C6H9N3O2)2Cl2对小麦的生态毒理效应

以冬小麦为实验材料,比较研究了(1)不同浓度配合物对小麦生长的影响;(2)相同浓度的CuC l2、配体C6H9N3O2和配合物Cu(C6H9N3O2)2C l2对冬小麦种子萌发、苗期生长及其保护酶活性的影响。结果表明:与对照相比,(1)不同浓度新配合物对小麦生长具有不同程度的抑制作用,随着浓度的增高抑制作用逐渐增大;(2)CuC l2、配合物Cu(C6H9N3O2)2C l2对小麦种子总淀粉酶活性、蛋白酶活性、萌发率、生长势、根长、株高、总生物量均具有显著的抑制作用,配合物Cu(C6H9N3O2)2C l2的抑制作用小于CuC l2,而配体C6H9N3O2对上述生物学参数具有促进作用;(3)CuC l2、配合物Cu(C6H9N3O2)2C l2处理引起膜脂过氧化,显著的提高了幼苗的M DA浓度,导致SOD、POD、CAT活性降低,CuC l2的抑制作用大于配合物Cu(C6H9N3O2)2C l2,而配体C6H9N3O2处理对SOD、POD、CAT活性的提高有促进作用。上述结果说明C6H9N3O2对CuC l2生理胁迫具有保护作用,结合态的Cu2 (配合物Cu(C6H9N3O2)2C l2)的毒性显著的降低。在此基础上探讨了配合物抑制小麦生长发育的生物学机制。     

外源γ-氨基丁酸对Ca(NO3)2胁迫下甜瓜幼苗NO3--N同化的影响

以盐敏感型甜瓜品种‘一品天下208’为试材,用80 mmol·L^-1 Ca(NO₃)₂模拟设施土壤盐渍化,采用深液流水培,研究外源 γ-氨基丁酸(GABA)对Ca(NO₃)₂胁迫下甜瓜幼苗硝态氮(NO₃^--N)同化的影响.结果表明: Ca(NO₃)₂胁迫显著降低了甜瓜幼苗体内硝酸还原酶(NR)、谷氨酰胺合酶(GS)和谷氨酸合酶(GOGAT)活性,增强了谷氨酸脱氢酶(GDH)、谷草转氨酶(GOT)和谷丙转氨酶(GPT)活性,导致铵态氮(NH₄⁺-N)和游离氨基酸含量增加,NO₃^--N和可溶性蛋白质含量下降,植株生长和光合作用受到严重抑制.Ca(NO₃)₂胁迫下,外源喷施GABA有效促进了甜瓜根系对NO₃^--N的吸收及其向地上部的转运,并通过增强NR、GS和GOGAT活性提高了甜瓜幼苗对NH₄⁺的同化力;通过抑制GDH脱氨作用减少了甜瓜幼苗体内NH₄⁺的释放量,从而缓解了盐诱导产生的NH₄⁺-N积累所造成的氨毒害作用;外源喷施GABA也能调节甜瓜组织中氨基酸代谢途径,促进蛋白质的合成.表明外源GABA能增强甜瓜幼苗对NO₃^--N的同化能力,调控氨基酸代谢,进而有效缓解Ca(NO₃)₂胁迫对甜瓜幼苗的盐伤害作用.     

1,25-(OH)2D3对去卵巢骨质疏松大鼠骨密度及OPG、RANKL表达的影响

目的:探讨1,25-(OH)2D3对去卵巢骨质疏松大鼠骨密度及OPG、RANKL表达的影响。方法选取6月龄雌性SD大鼠32只,随机分4组;空白组正常饲养,模型组制备去卵巢骨质疏松模型,假手术组按照模型组的流程给予开腹和缝线刺激,干预组在制备去卵巢骨质疏松模型的基础上给予1,25-(OH)2D3灌胃。分别于造模前后测定各组大鼠股骨BMD,并在造模最后一天取大鼠外周血和脊髓组织,采用Western Blotting检测OPG和RANKL的蛋白表达水平。结果:造模前,各组大鼠的体重和BMD无统计学差异(P0.05);造模后,与对照组相比,模型组大鼠体重显著升高,BMD显著降低;与模型组相比,干预组大鼠体重显著降低,BMD显著升高;各项组间差异均有统计学意义(P0.05)。与对照组相比,模型组OPG蛋白表达水平显著降低,假手术组无显著差异;与模型组相比,干预组大鼠OPG蛋白表达水平显著升高;RANKL变化趋势与OPG相反,且各项组间差异均有统计学意义(P0.05或P0.001)。结论:1,25-(OH)2D3能够改善雌激素降低引发的OPG/RANKL平衡失调,提高去卵巢骨质疏松大鼠的骨密度。     

甲状旁腺激素对成骨细胞中ClC-3 氯通道表达及成骨分化影响的研究

目的:观察甲状旁腺激素(PTH)对成骨细胞中Cl C-3氯通道表达及成骨分化影响,初步探索Cl C-3介导PTH在细胞成骨分化中的作用。方法:采用10-8M、10-9M、10-10M PTH持续刺激和间断刺激MC3T3-E1细胞72 h后,通过CCK-8试剂盒法检测MC3T3-E1细胞的增殖情况,Real-Time PCR法检测MC3T3-E1细胞中Clcn3及成骨相关基因Alp、Runx2的表达情况,免疫荧光法检测10-9M PTH不同给药方式下对Cl C-3蛋白表达的影响。结果 :经不同浓度PTH连续和间断处理72 h后,结果显示10-9 M PTH间断刺激的MC3T3-E1细胞的增殖能力最强,且其Alp、Runx2 m RNA表达均高于10-8 M组和10-10 M组(P<0.05),而相同浓度间断刺激的MC3T3-E1细胞成骨相关基因的表达均高于持续刺激组,以10-9M间断刺激组差异最显著(P<0.05),而10-8 M和10-10M均无统计学差异(P>0.05),10-9 M PTH刺激的MC3T3-E1细胞中Cl C-3蛋白表达也显著增加(P<0.05)。结论 :成骨细胞的Cl C-3氯通道能够响应PTH的刺激发生变化,并伴随着成骨相关基因Alp、Runx2表达的增强。     

1,25-二羟维生素D3的生物学效应

1,25-二羟维生素D3是维生素D3的活性形式,其生物学效应是由基因组与非基因组两种机制介导的。维生素D3除了具有钙磷代谢调节作用外,还具有其他更为广泛的生物学效应。1,25-二羟维生素D3能够抑制多种类型细胞的增殖,诱导细胞的凋亡和分化,调节机体免疫系统功能,保护中枢神经系统,以及保护基因等。     

24,25(OH)2D3 enhances the calcemic effect of 1,25(OH)2D3

The effect of 24,25(OH)2D3 on 1,25(OH)2D3-induced hypercalcemia was studied in normal rats. Serum (S) levels and urinary excretion of Ca2+ (UCaV) were measured in (a) control rats, (b) rats receiving a daily sc injection of 54 ng 1,25(OH)2D3, (c) rats receiving 24,25(OH)2D3 in the same dose and same manner, and (d) rats receiving 1,25(OH)2D3 + 24,25(OH)2D3. The animals were housed in metabolic cages and 24-hr urine specimens were collected. After 24 hr SCa2+ increased similarly with 1,25(OH)2D3 and with 1,25(OH)2D3 + 24,25(OH)2D3, while 24,25(OH)2D3 alone did not change SCa2+. UCaV after 24 hr increased significantly less (P less than 0.025) with 1,25(OH)2D3 + 24,25(OH)2D3 than with 1,25(OH)2D3 alone. After 5 days of 1,25(OH)2D3, SCa2+ rose from 5.1 +/- 0.15 to 6.29 +/- 0.08 whereas 1,25(OH)2D3 + 24,25(OH)2D3 effected a greater increase in SCa2+ up to 6.63 +/- 0.09 (P less than 0.01). 24,25(OH)2D3 alone did not change SCa2+. UCaV after 5 days of treatment rose similarly with 1,25(OH)2D3 and with 1,25(OH)2D3 + 24,25(OH)2D3. After 10 days of 1,25(OH)2D3 SCa2+ was 6.17 +/- 0.15 meq/liter while with the combination SCa2+ rose to 6.74 +/- 0.2 (P less than 0.025). 24,25(OH)2D3 alone did not change SCa2+. These results show that (a) 24,25(OH)2D3 alone does not alter SCa2+ in normal rats, (b) combined administration of 1,25(OH)2D3 + 24,25(OH)2D3 enhances the hypercalcemic response to 1,25(OH)2D3 without a parallel increase in UCaV, and (c) it is suggested that the effect of 24,25(OH)2D3 on serum Ca2+ level, at least partly, may result from its hypocalciuric effect.     

Bone specific binding sites for 1,25(OH)2D3 in magnesium deficiency

It has been reported that some hypoparathyroid patients with magnesium deficiency showed altered responses to vitamin D treatment. In the same way, in vitro bone studies have demonstrated the existence of a decrease in the 1,25-dihydroxyvitamin D3-induced resorption in bone as a result of magnesium deficiency. These findings suggest some kind of alteration in the 1,25(OH)2D3 in bone in magnesium deficiency. In the present work, using a binding assay based on the 1,25(OH)2D3 and 3H-1,25(OH)2D3 competition for the hormone binding sites in rat calvaria homogenates, a significant decrease in the number of 1,25(OH)2D3 specific binding sites has been found in calvaria incubated in magnesium-deficient medium compared to magnesium-replete ones. Alterations in the hormone-receptor affinity were not found. These results suggest that an alteration in the 1,25(OH)2D3 action on magnesium-deficient bone could be due, at least in part, to a decrease in the number of available vitamin D receptors in bone cells.     

Effects of 24,25(OH)2D3, 1,25(OH)2D3 and 25(OH)D3 on alkaline and tartrate-resistant acid phosphatase activities in fetal rat calvaria

The aim of this work was to evaluate the effects of 24,25-dihydroxyvitamin D3, 24,25(OH)2D3, on alkaline phosphatase (AP) and tartrate-resistant acid phosphatase (TRAP) activities in fetal rat calvaria cultures. These actions were compared with those of 1,25-dihydroxyvitamin D3, 1,25(OH)2D3, and 25-hydroxyvitamin D3, 25(OH)D3, in similar experimental conditions. At 10 min, 30 min and at 24 h incubation time, 1,25(OH)2D3 (10(-10)M) and 25(OH)D3 (10(-7) M) produced a significant increase in AP and TRAP activities compared to control group (without vitamin D metabolites). However, 24,25(OH)2D3 (10(-7) M) only produced effects on phosphatase activities similar to those produced by 1,25(OH)2D3 and 25(OH)D3, after 24 h incubation time. These findings suggest that 1,25(OH)2D3 and 25(OH)2D3 could carry out actions in minutes (nongenomic mechanism), while 24,25(OH)2D3 needs longer periods of time to perform its biological actions (genomic mechanism).     

1,25(OH)2D3 Deficiency Induces Colon Inflammation via Secretion of Senescence-Associated Inflammatory Cytokines

Epidemiological studies showed that 1,25-Dihydroxyvitamin D[1,25(OH)₂D₃] insufficiency appears to be associated with aging and colon cancer while underlying biological mechanisms remain largely unknown. Inflammatory bowel disease is one of the risk factors for colon cancer. In this study, we investigated whether 1,25(OH)₂D₃ deficiency has an impact on the colon of 25-hydroxyvitamin D 1α-hydroxylase knockout [Cyp27b1^−/−] mice fed on a rescue diet (high calcium, phosphate, and lactose) from weaning to 10 months of age. We found that 1,25(OH)₂D₃ deficient mice displayed significant colon inflammation phenotypes including shortened colon length, thinned and disordered mucosal structure, and inflammatory cell infiltration. DNA damage, cellular senescence and the production of senescence-associated inflammatory cytokines were also increased significantly in the colon of Cyp27b1^−/−mice. Furthermore, the levels of ROS in the colon were increased significantly, whereas the expression levels of antioxidative genes were down-regulated dramatically in the colon of Cyp27b1^−/−mice. Taken together, our results demonstrated that 1,25(OH)₂D₃ deficiency could induce colon inflammation, which may result from increased oxidative stress and DNA damage, subsequently, induced cell senescence and overproduction of senescence-associated secretory factors. Therefore, our findings suggest that 1,25(OH)₂D₃ may play an important role in preventing the development and progression of colon inflammation and colon cancer.     

Effects of 1,25(OH)2D3 and 25(OH)D3 on C2C12 Myoblast Proliferation,Differentiation, and Myotube Hypertrophy

An adequate vitamin D status is essential to optimize muscle strength. However, whether vitamin D directly reduces muscle fiber atrophy or stimulates muscle fiber hypertrophy remains subject of debate. A mechanism that may affect the role of vitamin D in the regulation of muscle fiber size is the local conversion of 25(OH)D to 1,25(OH)₂D by 1α‐hydroxylase. Therefore, we investigated in a murine C2C12 myoblast culture whether both 1,25(OH)₂D₃ and 25(OH)D₃ affect myoblast proliferation, differentiation, and myotube size and whether these cells are able to metabolize 25(OH)D₃ and 1,25(OH)₂D₃. We show that myoblasts not only responded to 1,25(OH)₂D₃, but also to the precursor 25(OH)D₃ by increasing their VDR mRNA expression and reducing their proliferation. In differentiating myoblasts and myotubes 1,25(OH)₂D₃ as well as 25(OH)D₃ stimulated VDR mRNA expression and in myotubes 1,25(OH)₂D₃ also stimulated MHC mRNA expression. However, this occurred without notable effects on myotube size. Moreover, no effects on the Akt/mTOR signaling pathway as well as MyoD and myogenin mRNA levels were observed. Interestingly, both myoblasts and myotubes expressed CYP27B1 and CYP24 mRNA which are required for vitamin D₃ metabolism. Although 1α‐hydroxylase activity could not be shown in myotubes, after treatment with 1,25(OH)₂D₃ or 25(OH)D₃ myotubes showed strongly elevated CYP24 mRNA levels compared to untreated cells. Moreover, myotubes were able to convert 25(OH)D₃ to 24R,25(OH)₂D₃ which may play a role in myoblast proliferation and differentiation. These data suggest that skeletal muscle is not only a direct target for vitamin D₃ metabolites, but is also able to metabolize 25(OH)D₃ and 1,25(OH)₂D₃. J. Cell. Physiol. 231: 2517–2528, 2016. © 2016 The Authors. Journal of Cellular Physiology Published by Wiley Periodicals, Inc.     

24,25(OH)2D3 enhances the calcemic effect of 1,25(OH)2D3 in PTX rats

The effect of 24,25(OH)2D3 on 1,25(OH)2D3-induced hypercalcemia was studied in parathyroidectomized (PTX) rats for 10 days. Serum (S) and urinary Ca excretion (UCaV) were measured in (a) control rats, (b) rats receiving a daily sc injection of 54 ng 1,25(OH)2D3, (c) rats receiving 24,25(OH)2D3 in the same dose and same manner, and (d) rats receiving 1,25(OH)2D3 + 24,25(OH)2D3. Our results show that (i) 24,25(OH)2D3 alone does not increase SCa2+ in PTX rats, (ii) combined administration of 1,25(OH)2D3 + 24,25(OH)2D3 enhances the hypercalcemic response to 1,25(OH)2D3 without a parallel increase in UCaV, (iii) combined administration of 1,25(OH)2D3 + 24,25(OH)2D3 reduces the rise in urinary excretion of Ca2+ compared with that of rats receiving 1,25(OH)2D3 alone for 10 days, and (iv) these alterations are independent of parathyroid hormone.     

Phosphate uptake in chick kidney cells: effects of 1,25(OH)2D3 and 24,25(OH)2D3

Phosphate homeostasis is controlled in part by absorption from the intestine, and reabsorption in the kidney. While the effect of Vitamin D metabolites on enterocytes is well documented, in the current study we assess selected responses in primary cultures of kidney cells. Time course studies revealed a rapid stimulation of phosphate uptake in cells treated with 1,25(OH)(2)D(3), relative to controls. Dose-response studies indicated a biphasic curve with optimal stimulation at 300 pM 1,25(OH)(2)D(3) and inhibition at 600 pM seco-steroid. Antibody 099--against the 1,25D(3)-MARRS receptor - abolished stimulation by the steroid hormone. Moreover, phosphate uptake was mediated by the protein kinase C pathway. The metabolite 24,25(OH)(2)D(3), which was found to inhibit the rapid stimulation of phosphate uptake in intestinal cells, had a parallel effect in cultured kidney cells. Finally, the 24,25(OH)(2)D(3) binding protein, catalase, was assessed for longer term down regulation. In both intestinal epithelial cells and kidney cells incubated with 24,25(OH)(2)D(3) for 5-24h, both the specific activity of the enzyme and protein levels were decreased relative to controls, while 1,25(OH)(2)D(3) increased both parameters over the same time periods. We conclude that the Vitamin D metabolites have similar effects in both kidney and intestine, and that 24,25(OH)(2)D(3) may have effects at the level of gene expression.     

Effect of 1,25(OH)2D3 on bone morphogenetic protein-3 mRNA expression

Bone morphogenetic proteins (BMPs) are members to the transforming growth factor-beta superfamily. They induce ectopic bone formation in rat and are pleiotropic initiators of inducible osteogenic precursor cells. A lot of reports have studied the presence of BMPs and their effects on bone marker expression in many different cell lines, however none describe the regulation of BMP3 by different factors and expression conditions. When a human bone marrow stromal cell (HBMSC) culture was treated simultaneously with 1,25(OH)2D3 (10(-8) M) and BMP3 (2.5 ng/ml), the total osteocalcin content in the cell layer and in the culture medium was higher than when the culture was treated with either factor alone (162%). To elucidate this synergistic activity, Northern blot analysis was done to study the effect of 1,25(OH)2D3 on BMP3 mRNA expression. Several human cell lines (MNNG, U-2OS, MG-63, KHOS, TE85, HOS) and HBMSC were treated by 1,25(OH)2D3 (10(-8) M for 24 h). Purified mRNA from treated and untreated cells were denatured using glyoxal and dimethylsulfoxide, and were fractionated on a 1% agarose gel. After electrophoresis, RNA were blotted onto a nylon membrane and incubated with 32P-labeled BMP3 and GAPDH riboprobes. Northern blot analysis revealed that, the BMP3 mRNA level was increased in a few cell lines (MG-63, HBMSC, HOS) after the addition of 1,25(OH)2D3 when compared to the untreated cells (127%+/-1; 130.5%+/-19.5; 207%+/-14). An higher stimulation was observed in HBMSC primary culture when compared to differentiated HBMSC. In view of these results, we now investigate the following hypothesis: does the BMP3 promoter exhibit the vitamin D receptor response like the osteocalcin gene?     

Biologic effect of 1,24(R)(OH)2D3 versus 1,25(OH)2D3 administration in chronic renal failure

1,24(R)(OH)2D3 is a synthetic analogue of 1,25(OH)2D3 which binds to the same receptors as the physiologic metabolite with a lower affinity. The aim of the present study was to compare the activity of 1,24(R)(OH)2D3 and 1,25(OH)2D3 on several target organs in patients with chronic renal failure. Treatment with 1,24(R)(OH)2D3 at doses of either 1 or 2 μg daily was carried out in two groups of 9 patients, with serum creatinine of 4.61 ± 1.59 and 4.66 ± 1.46 mg/dl, respectively. Doses of 1,25(OH)2D3 were 0.5 and 1 μg daily and were administered to 9 and 13 patients, serum creatinine of 4.52 ± 1.67 and 4.3 ± 1.16 mg/dl, respectively. Treatment periods were of 2 weeks. Administration of 1,25(OH)2D3, 1 μg, induced significant increments of intestinal calcium absorption (ICA), ionized calcium, osteocalcin, serum creatinine, urine Ca/GFR, and a decrease in iPTH. 1,25(OH)2D3, 0.5 μg, induced a significant increase in ICA and osteocalcin and a decrease in iPTH. Similarly 1,24(OH)2D3, 2 μg daily, significantly stimulated ICA and raised serum levels of osteocalcin and creatinine while lowering serum iPTH. In addition, 1,24(R)(OH)2D3 administration induced a significant fall of serum 1,25(OH)2D3. Following 1 μg, only osteocalcin increased. Therefore, the dose of 2 μg of 1,24(R)(OH)2D3 has biologic activity similar to 0.5 μg 1,25(OH)2D3 (4:1). However the activity ratio on osteocalcin production appears to be 2:1. In addition, 1,24(R)(OH)2D3 is able to inhibit renal tubular 1-hydroxylase. In conclusion 1,24(R)(OH)2D3 may prove to be useful in the treatment of metabolic bone disease.